Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus

被引:27
|
作者
Lv, Jing [1 ]
Guo, Lei [2 ]
Wang, Ji-Han [1 ]
Yan, Yu-Zhu [1 ]
Zhang, Jun [3 ]
Wang, Yang-Yang [4 ]
Yu, Yan [1 ]
Huang, Yun-Fei [2 ]
Zhao, He-Ping [1 ]
机构
[1] Xi An Jiao Tong Univ, Honghui Hosp, Dept Clin Lab, 555 You Yi Dong Rd, Xian 710054, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spinal Surg, Xian 710054, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Gastroenterol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
[4] Tenth Res Inst Telecommun Technol, Xian 710000, Shaanxi, Peoples R China
关键词
Esophageal adenocarcinoma; Differentially expressed genes; Barrett's esophagus; Transcription factors; Microarray; SURVEILLANCE; PROGRESSION; DIAGNOSIS; COL1A1; CANCER; RISK;
D O I
10.3748/wjg.v25.i2.233
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Esophageal adenocarcinoma (EAC) is an aggressive disease with high mortality and an overall 5-year survival rate of less than 20%. Barrett's esophagus (BE) is the only known precursor of EAC, and patients with BE have a persistent and excessive risk of EAC over time. Individuals with BE are up to 30-125 times more likely to develop EAC than the general population. Thus, early detection of EAC and BE could significantly improve the 5-year survival rate of EAC. Due to the limitations of endoscopic surveillance and the lack of clinical risk stratification strategies, molecular biomarkers should be considered and thoroughly investigated. AIM To explore the transcriptome changes in the progression from normal esophagus (NE) to BE and EAC. METHODS Two datasets from the Gene Expression Omnibus (GEO) in NCBI Database (https://www.ncbi.nlm.nih.gov/geo/) were retrieved and used as a training and a test dataset separately, since NE, BE, and EAC samples were included and the sample sizes were adequate. This study identified differentially expressed genes (DEGs) using the R/Bioconductor project and constructed trans-regulatory networks based on the Transcriptional Regulatory Element Database and Cytoscape software. Enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) terms was identified using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics Resources. The diagnostic potential of certain DEGs was assessed in both datasets. RESULTS In the GSE1420 dataset, the number of up-regulated DEGs was larger than that of down-regulated DEGs when comparing EAC vs NE and BE vs NE. Among these DEGs, five differentially expressed transcription factors (DETFs) displayed the same trend in expression across all the comparison groups. Of these five DETFs, E2F3, FOXA2, and HOXB7 were up-regulated, while PAX9 and TFAP2C were down-regulated. Additionally, the majority of the DEGs in trans-regulatory networks were up-regulated. The intersection of these potential DEGs displayed the same direction of changes in expression when comparing the DEGs in the GSE26886 dataset to the DEGs in trans-regulatory networks above. The receiver operating characteristic curve analysis was performed for both datasets and found that TIMP1 and COL1A1 could discriminate EAC from NE tissue, while REG1A, MMP1, and CA2 could distinguish BE from NE tissue. DAVID annotation indicated that COL1A1 and MMP1 could be potent biomarkers for EAC and BE, respectively, since they participate in the majority of the enriched KEGG and GO terms that are important for inflammation and cancer. CONCLUSION After the construction and analyses of the trans-regulatory networks in EAC and BE, the results indicate that COL1A1 and MMP1 could be potential biomarkers for EAC and BE, respectively.
引用
收藏
页码:233 / 244
页数:12
相关论文
共 50 条
  • [31] Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus
    Wolf, W. Asher
    Pasricha, Sarina
    Cotton, Cary
    Li, Nan
    Triadafilopoulos, George
    Muthusamy, V. Raman
    Chmielewski, Gary W.
    Corbett, F. Scott
    Camara, Daniel S.
    Lightdale, Charles J.
    Wolfsen, Herbert
    Chang, Kenneth J.
    Overholt, Bergein F.
    Pruitt, Ron E.
    Ertan, Atilla
    Komanduri, Srinadh
    Infantolino, Anthony
    Rothstein, Richard I.
    Shaheen, Nicholas J.
    GASTROENTEROLOGY, 2015, 149 (07) : 1752 - +
  • [32] Histological evaluation of PAXgene tissue fixation in Barrett's esophagus and esophageal adenocarcinoma diagnostics
    Barroux, Melissa
    Horstmann, Julia
    Fricke, Lisa
    Schoemig, Linus
    Werner, Martin
    Kraynova, Ekaterina
    Kamaradova, Katerina
    Flejou, Jean-Francois
    Maerkel, Bruno
    Kumarasinghe, M. Priyanthi
    Vieth, Michael
    Westerhoff, Maria
    Patil, Deepa T.
    Steiger, Katja
    Becker, Karl-Friedrich
    Weichert, Wilko
    Schmid, Roland M.
    Quante, Michael
    Slotta-Huspenina, Julia
    VIRCHOWS ARCHIV, 2023, 482 (05) : 887 - 898
  • [33] Non-coding RNAs in thoracic disease: Barrett's esophagus and esophageal adenocarcinoma
    Sheng, Siyuan
    Guo, Jianhui
    Lu, Chuangang
    Hu, Xia
    CLINICA CHIMICA ACTA, 2025, 571
  • [34] Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma
    Amlashi, Fatemeh G.
    Wang, Xuemei
    Davila, Raquel E.
    Maru, Dipen M.
    Bhutani, Manoop S.
    Lee, Jeffrey H.
    Weston, Brian R.
    Kaya, Dilsa Mizrak
    Vassilakopoulou, Maria
    Harada, Kazuto
    Murphy, Mariela A. Blum
    Rice, David C.
    Hofstetter, Wayne L.
    Davila, Marta
    Nguyen, Quynh-nhu
    Ajani, Jaffer A.
    ONCOLOGY, 2018, 95 (02) : 81 - 90
  • [35] DCLK1 Is Detectable in Plasma of Patients with Barrett's Esophagus and Esophageal Adenocarcinoma
    Whorton, Joshua
    Sureban, Sripathi M.
    May, Randal
    Qu, Dongfeng
    Lightfoot, Stan A.
    Madhoun, Mohammad
    Johnson, Milton
    Tierney, William M.
    Maple, John T.
    Vega, Kenneth J.
    Houchen, Courtney W.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (02) : 509 - 513
  • [36] Challenges in Determining the Role of Microbiome Evolution in Barrett's Esophagus and Progression to Esophageal Adenocarcinoma
    Guccione, Caitlin
    Yadlapati, Rena
    Shah, Shailja
    Knight, Rob
    Curtius, Kit
    MICROORGANISMS, 2021, 9 (10)
  • [37] Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia
    I. Leeuwenburgh
    P. Scholten
    T. J. Caljé
    R. J. Vaessen
    H. W. Tilanus
    B. E. Hansen
    E. J. Kuipers
    Digestive Diseases and Sciences, 2013, 58 : 244 - 252
  • [38] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [39] Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers
    Grady, William M.
    Yu, Ming
    Markowitz, Sanford D.
    Chak, Amitabh
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (12) : 2486 - 2494
  • [40] Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma
    Rajendra, Shanmugarajah
    Sharma, Prateek
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (03) : 409 - +